RE:RE:RE:RE:RE:Products Submitted for Certain Markets ...R&D in drug development would give GUD a boost like no other component in GUD operational structure. Selling generics drugs with low margin in poor countries is not going to make a dent in GUD share price even if the in future GUD will have a low PE The market will discount the risk of where they operate. Simply look at gold stocks. Share price reflect the risks of where they operate. As for generic take a look at Teva and others and then compare them to biotech doing R&D for new drugs. It is a no brainer. I think that GBT is doing some R&D with GILD as I had read it on GBT website months back. Again now that GBT is fully owned by GUD it is paramount for JG to inform shareholders on all aspects and where GUD is heading and not having shareholders guessing. Enough of not showing his hands for six Years. If he does not the market will lean on the negative given LATAM operation.